Ad
ARWR - Arrowhead Pharmaceuticals Stock Trading
About | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
Not available
Quote | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
| Last: | $26.93 |
|---|---|
| Change Percent: | 0.23% |
| Open: | $26.33 |
| Close: | $26.93 |
| High: | $27.31 |
| Low: | $26.04 |
| Volume: | 759,781 |
| Last Trade Date Time: | 09/28/2023 03:00:00 am |
News | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
-
2023-09-26 15:08:59 ET More on Ionis Pharmaceuticals Ionis Pharmaceuticals: Mid-Sized Pharma Is A Strong Buy Opportunity For All-Comers Novartis and Ionis in pact for new cardiovascular therapy AstraZeneca-Ionis deal for eplontersen expands to Latin America S...
-
- Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung - Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma Demonstrate Deep and Durable Gene Silencing - Promising Preclinical Data Across Multiple Gene Targets Suggest Potentially Broad Applications f...
Message Board Posts | Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR)
| Subject | By | Source | When |
|---|---|---|---|
| whytestocks: $ARWR News Article - Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday | whytestocks | investorshangout | 04/25/2023 3:35:46 PM |
| $ARWR still ascending. | MiamiGent | investorshub | 01/13/2023 4:36:57 PM |
| whytestocks: $ARWR News Article - Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment | whytestocks | investorshangout | 12/20/2022 4:25:49 PM |
| Arrowhead is an amazing company. Gene silencing | jimmy667 | investorshub | 10/22/2022 8:11:09 AM |
| whytestocks: $ARWR News Article - 5 Top Biotech Stocks To Watch In July 2022 | whytestocks | investorshangout | 06/30/2022 6:55:50 PM |
Arrowhead Pharmaceuticals Inc. Company Name:
ARWR Stock Symbol:
NASDAQ Market:
Ad
-
Christopher Anzalone, Chief Executive Officer at Arrowhead Pharma (NASDAQ:ARWR), reported a large acquisition of company stock options on September...
-
- Arrowhead Expands the Reach of RNAi Therapies to Address Diseases in the Lung - Late-Breaking Clinical Data for ARO-RAGE for Treatment of Asthma Demonstrate Deep and Durable Gene Silencing - Promising Preclinical Data Across Multiple Gene Targets Suggest Potentially Broad Applications f...
-
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve ...